Format

Send to

Choose Destination
Cancer. 2015 Aug 15;121(16):2840-8. doi: 10.1002/cncr.29430. Epub 2015 Apr 29.

Health care utilization and end-of-life care for older patients with acute myeloid leukemia.

Author information

1
Department of Oncology, Massachusetts General Hospital, Boston, Massachusetts.
2
Dana-Farber Cancer Institute, Center for Outcomes and Policy Research, Harvard Medical School, Boston, Massachusetts.
3
Department of Hematological Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts.
4
Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, North Carolina.

Abstract

BACKGROUND:

Health care utilization in older adults (age ≥60 years) with acute myeloid leukemia (AML) has not been well studied.

METHODS:

We conducted a retrospective analysis of 330 consecutive older patients who were diagnosed with AML between May 1, 2005 and December 23, 2011, at 2 hospitals in Boston to examine their health care utilization and end-of-life care. Using multivariable logistic and linear regression models adjusting for covariates, we also compared health care utilization between patients who received intensive induction chemotherapy (n = 197; cytarabine/ anthracycline combination) versus nonintensive chemotherapy (n = 133; single-agent therapy).

RESULTS:

The median number of hospitalizations for the entire cohort was 4.2 (range, 1-18 hospitalizations). Patients who died spent a mean of 28.3% of their life after diagnosis in the hospital and 13.8% of their life attending outpatient clinic appointments. Although the majority of patients (87.9%) died during the 2-year follow-up period, a minority received palliative care (16.2%) or hospice (23.1%) services. Within 30 days of death, 84.5% of patients were hospitalized, and 61% died in the hospital. Among the patients who died, those who received intensive induction therapy (vs nonintensive therapy) spent 30% more of their life after diagnosis in the hospital (P < .0001) and were less likely to receive hospice services (odds ratio, 0.45; P = .05).

CONCLUSIONS:

The current findings highlight the intensity of health care utilization among older patients with AML, regardless of treatment modality. Despite the poor prognosis, palliative care and hospice services are rarely used. Future work should study novel health care delivery models to optimize care throughout the course of illness and at the end of life.

KEYWORDS:

acute myeloid leukemia; end-of-life care; health care utilization; palliative care

PMID:
25926135
PMCID:
PMC4418225
DOI:
10.1002/cncr.29430
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center